British Journal of Haematology · 2016 · 27 citations · 35 references
MedicineCell BiologyOncologyHematopathologyMolecular OncologyNeoplasiaBone Marrow EvaluationBone Marrow PathologyClinical HematologyImmuno-oncology BiomarkersMinimal Residual DiseaseMultiple MyelomaBortezomib TherapyBortezomib-based TherapyHypoxiaMinimal Residual Disease MarkersMultiple Myeloma TherapyMultiple Myeloma TreatmentPrognostic Marker AssessmentPrognostic Marker Evaluation
CD138 (also termed SDC1) has been the gold-standard surface marker to detect multiple myeloma (MM) cells for decades; however, drug-resistant residual and circulating MM cells were shown to have lower expression of this marker. In this study, we have shown that residual MM cells following bortezomib treatment are hypoxic. This combination of drug exposure and hypoxia down-regulates their CD138 expression, thereby making this marker unsuitable for detecting residual or other hypoxic MM cells, such as circulating tumour cells, in MM. Hence, we developed an alternative biomarker set which detects myeloma cells independent of their hypoxic and CD138 expression status in vitro, in vivo and in primary MM patients. The new markers were able to identify a clonal CD138-negative population as minimal residual disease in the bone marrow and peripheral blood of MM patients. Further investigation to characterize the role of this population as a prognostic marker in MM is warranted.
35
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Robert A. Kyle, Morie A. Gertz, Thomas E. Witzig et al. · Mayo Clinic Proceedings · 2003 · 2.4K citations
Medicine, Hematology, Oncology +10
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
William Matsui, Qiuju Wang, James Barber et al. · Cancer Research · 2008 · 538 citations · Full text
Medicine, Oncology, Pharmacology +15